2226654-05-1
2226654-05-1
Chemical Structure
Ziltivekimab
Synonym(s): COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
- CAS No.: 2226654-05-1
- Formula:N/A
- Molecular Weight:(145.39 kDa)
IUPAC Name: 6-(difluoromethyl)-3-fluoropicolinaldehyde
SMILES: [Ziltivekimab]
Biological Activity: Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ziltivekimab | 99.75% | Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. [Content Brief]
- [2]. Pergola PE, et al. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2024;35(1):74-84. [Content Brief]
